Diabetes patients admitted for acute exacerbations of COPD have longer hospital stay

June 21, 2010

A new study in the journal Respirology reveals that patients with diabetes who are hospitalized with acute exacerbations of chronic obstructive pulmonary disease (COPD) experience longer time in the hospital and are also at an increased risk of death, compared to those without diabetes.

High blood sugar may cause more severe infections due to impairment of immune responses. Researchers led by Dr. Ali Parappil of the Department of Respiratory Medicine, Liverpool Hospital in Australia reviewed records of patients admitted with acute exacerbations of COPD during 2007. They examined data on the presence of diabetes, length of stay, disease severity, and other co-morbidities.

The results show a trend towards an increased length of hospital stay for patients with diabetes. The average length of stay for patients without diabetes was 6.5 days but, among the 53 (22%) admissions in patients with diabetes the average length of stay was 7.8 days, which was 10.3% longer (after adjusting for other co-morbidities). Diabetes patients were also at increased risk of death during the hospitalization (8% vs 4%).

"Taken together with other studies, our study shows that diabetes was an adverse prognostic factor in COPD patients," said Parappil. "We believe that better control of diabetes in patients with COPD could improve outcomes; in particular, reducing length of hospital stays and risk of death."
-end-
This study is published in the journal Respirology. Media wishing to receive a PDF of this article may contact healthnews@wiley.com

Full citation: "Effect of Comorbid Diabetes on Length of Stay and Risk of Death in Patients Admitted with Acute Exacerbations of COPD. Ali Parappil, Barbara Depczynski, Peter Collett, and Guy B. Marks. June 2010.

About the Author: Ali Parappil is affiliated with the Royal Prince Alfred Hospital in Camperdown NSW.

About the Journal


Respirology
is a journal of international standing, publishing peer-reviewed articles of scientific excellence in clinical and experimental respiratory biology and disease and its related fields of research including thoracic surgery, internal medicine, immunology, intensive and critical care, epidemiology, cell and molecular biology, pathology, pharmacology and physiology. The journal is published by Wiley-Blackwell on behalf of the Asian Pacific Society of Respirology.

About Wiley-Blackwell


Wiley-Blackwell is the international scientific, technical, medical, and scholarly publishing business of John Wiley & Sons, with strengths in every major academic and professional field and partnerships with many of the world's leading societies. Wiley-Blackwell publishes nearly 1,500 peer-reviewed journals and 1,500+ new books annually in print and online, as well as databases, major reference works and laboratory protocols. For more information, please visit www.wileyblackwell.com or www.interscience.wiley.com.

Wiley

Related Diabetes Articles from Brightsurf:

New diabetes medication reduced heart event risk in those with diabetes and kidney disease
Sotagliflozin - a type of medication known as an SGLT2 inhibitor primarily prescribed for Type 2 diabetes - reduces the risk of adverse cardiovascular events for patients with diabetes and kidney disease.

Diabetes drug boosts survival in patients with type 2 diabetes and COVID-19 pneumonia
Sitagliptin, a drug to lower blood sugar in type 2 diabetes, also improves survival in diabetic patients hospitalized with COVID-19, suggests a multicenter observational study in Italy.

Making sense of diabetes
Throughout her 38-year nursing career, Laurel Despins has progressed from a bedside nurse to a clinical nurse specialist and has worked in medical, surgical and cardiac intensive care units.

Helping teens with type 1 diabetes improve diabetes control with MyDiaText
Adolescence is a difficult period of development, made more complex for those with Type 1 diabetes mellitus (T1DM).

Diabetes-in-a-dish model uncovers new insights into the cause of type 2 diabetes
Researchers have developed a novel 'disease-in-a-dish' model to study the basic molecular factors that lead to the development of type 2 diabetes, uncovering the potential existence of major signaling defects both inside and outside of the classical insulin signaling cascade, and providing new perspectives on the mechanisms behind insulin resistance in type 2 diabetes and possibly opportunities for the development of novel therapeutics for the disease.

Tele-diabetes to manage new-onset diabetes during COVID-19 pandemic
Two new case studies highlight the use of tele-diabetes to manage new-onset type 1 diabetes in an adult and an infant during the COVID-19 pandemic.

Genetic profile may predict type 2 diabetes risk among women with gestational diabetes
Women who go on to develop type 2 diabetes after having gestational, or pregnancy-related, diabetes are more likely to have particular genetic profiles, suggests an analysis by researchers at the National Institutes of Health and other institutions.

Maternal gestational diabetes linked to diabetes in children
Children and youth of mothers who had gestational diabetes during pregnancy are at increased risk of diabetes themselves, according to new research published in CMAJ (Canadian Medical Association Journal).

Two diabetes medications don't slow progression of type 2 diabetes in youth
In youth with impaired glucose tolerance or recent-onset type 2 diabetes, neither initial treatment with long-acting insulin followed by the drug metformin, nor metformin alone preserved the body's ability to make insulin, according to results published online June 25 in Diabetes Care.

People with diabetes visit the dentist less frequently despite link between diabetes, oral health
Adults with diabetes are less likely to visit the dentist than people with prediabetes or without diabetes, finds a new study led by researchers at NYU Rory Meyers College of Nursing and East Carolina University's Brody School of Medicine.

Read More: Diabetes News and Diabetes Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.